Active Surveillance

What is Active Surveillance?

  • Involves close monitoring of small, slow-growing prostate cancer with relatively normal-looking cells (as determined by your biopsy results);
  • May be appropriate if you are an older man who may be more likely to develop other (age-related) conditions that may have a greater impact on your health;
  • Doesn’t involve invasive procedures
  • Doesn’t involve drugs
  • No side effects
Your prostate cancer will be monitored closely and may involve the following procedures:
 
  • Regular PSA tests and digital rectal exams
  • Monitoring PSA doubling time (this may mean having a PSA test done every 3-6 months)
    • PSA doubling time refers to how long it takes for a man’s level of prostate-specific antigen to double
  • Occasional repeat biopsies
  • Follow-up bone scan and/or CT scan to monitor disease progression
You will be offered more aggressive treatment at the first sign your prostate cancer has progressed or tumour has grown. Your doctor will discuss the advantages and disadvantages of each treatment option.  You should know that active surveillance is not a cure for prostate cancer.  It also carries the risk that your prostate cancer might spread (metastasize).  This is why regular monitoring is so important. 

You may have heard of the term “watchful waiting”.  Watchful waiting involves having no treatment for your prostate cancer.  Rather than treating the prostate cancer, your doctor will wait until you start having symptoms and treat those, usually with medication. The goal of watchful waiting is not to cure your prostate cancer, but treat your symptoms to make you feel better.
 
Related Links




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
‘Doing it for Dads’ this Father’s Day: Albertans unite for prostate cancer research

Building Trades of Alberta and multiple community fundraisers have raised $330,000 and counting  Calgary – May 27th, 2015:  In the lead-up to Father’s Day, Prostate Cancer Canada (PCC) is excited to announce that Albertans have demonstrated significant leadership by banding together to raise over $330,000 and counting in important research dollars and awareness for prostate cancer, the most common cancer to affect men. More

Groundbreaking Research Moves One Step Closer to Personalizing Prostate Cancer Treatment

Movember Foundation, Prostate Cancer Canada and the Ontario Institute for Cancer Research funded research breakthrough published in Nature Genetics   TORONTO, ON (May 25, 2015) The results of groundbreaking genetics research in Canada, funded by the Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada, has identified a unique sub-type of prostate cancer that will help clinicians develop more personalized treatments for their patients, ensure that fewer men undergo unnecessary treatments and improve their chances of survival. More


Click here for news archive